Trials in Boston, Massachusetts
Here are the top 10 medical studies for colorectal cancer in Boston, Massachusetts
Popular Filters
Phase 3 Trials
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Billerica, Massachusetts
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Small Molecule
MRTX849 + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
Chemotherapy Tailored by ctDNA Status for Colon Cancer
Recruiting1 awardPhase 2 & 3
Glastonbury, Connecticut
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Checkpoint Inhibitor
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Trials With No Placebo
KRAS G12C Inhibitor
GDC-6036 for KRAS G12C-Mutated Cancers
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called GDC-6036 in patients with advanced or metastatic solid tumors that have a KRAS G12C mutation. The drug works by blocking a faulty part of the cancer cells' genetic code to stop their growth.
Monoclonal Antibodies
BCA101 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
Springfield, Massachusetts
This trial is testing a new drug called TPST-1495 alone and with pembrolizumab to treat various advanced cancers. It focuses on patients whose cancers have no remaining standard treatments. TPST-1495 blocks signals that help tumors grow, while pembrolizumab helps the immune system fight the cancer. Pembrolizumab has been widely studied and used in various cancers, showing effectiveness and safety.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.